LN group (n=20) | non-LN group (n=54) | |
---|---|---|
Age (y) mean±SD | 26.6±5.1* | 30.5±9.3 |
Gender (men/women) % | 20/80* | 0/100 |
Caucasian (W/N-W) % | 30/70 | 33/67 |
Disease duration of SLE (months) mean±SD | 30±26.3* | 80.8±61.3 |
Mex-SLEDAI mean±SD | 9.20±4.57* | 0.07±0.38 |
Dipstick positive hematuria - (1+ to 4+), % (n) | 100.0 (20)* | 0.0 (0) |
Dysmorphic erythrocyte, % (n) | 70.0 (14)* | 1.8 (1) |
Erythrocyte, granular, fatty and waxy casts, % (n) | 70.0 (14)* | 7.4 (4) |
Oval fat bodies, % (n) | 80.0 (16)* | 1.8 (1) |
Erythrocytes sedimentation rate/HPF mean±SD | 33.8±16.3* | 1.9±1.7 |
Dipstick positive proteinuria (1+ to 4+), % (n) | 100.0 (20)* | 5.6 (3) |
Pr/Cr ratio (mg/mg) mean±SD | 4.89±4.30* | 0.37±0.26 |
24-h Proteinuria (g/L) mean±SD | 4.77±3.58* | 0.23±0.20 |
Serum creatinine (μmol/L) mean±SD | 140.42±73.70* | 70.90±16.92 |
eGFR (mL/min) mean±SD | 57.27±28.02* | 95.22±23.94 |
Creatinine clearance (mL/min/1.73 m 2 ) mean±SD | 60.33±24.99* | 92.68±22.97 |
Serum C3 (mg/L) mean±SD | 62.83±42.40* | 131.30±64.24 |
Serum C4 (mg/L) mean±SD | 27.87±14.92* | 44.48±18.38 |
Anti-dsDNA title mean±SD | 98.95±50.54* | 17.22±9.20 |